EUVIMEDEUVIMED entdecken
Crossref

Myeloma and DNA damage

Giovanni Tonon iD

Blood · 2024

DOI: 10.1182/blood.2023021384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Giovanni Tonon. Beteiligte Einrichtung: Università Vita-Salute San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA-damaging agents have represented the first effective treatment for the blood cancer multiple myeloma, and after 65 years since their introduction to the clinic, they remain one of the mainstay therapies for this disease. Myeloma is a cancer of plasma cells. Despite exceedingly slow proliferation, myeloma cells present extended genomic rearrangements and intense genomic instability, starting at the premalignant stage of the disease. Where does such DNA damage stem from? A reliable model argues that the powerful oncogenes activated in myeloma as well the phenotypic peculiarities of cancer plasma cells, including the dependency on the proteasome for survival and the constant presence of oxidative stress, all converge on modulating DNA damage and repair. Beleaguered by these contraposing forces, myeloma cells survive in a precarious balance, in which the robust engagement of DNA repair mechanisms to guarantee cell survival is continuously challenged by rampant genomic instability, essential for cancer cells to withstand hostile selective pressures. Shattering this delicate equilibrium has been the goal of the extensive use of DNA-damaging agents since their introduction in the clinic, now enriched by novel approaches that leverage upon synthetic lethality paradigms. Exploiting the impairment of homologous recombination caused by myeloma genetic lesions or treatments, it is now possible to design therapeutic combinations that could target myeloma cells more effectively. Furthermore, DNA-damaging agents, as demonstrated in solid tumors, may sensitize cells to immune therapies. In all, targeting DNA damage and repair remains as central as ever in myeloma, even for the foreseeable future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansDNA DamageDNA RepairGenomic InstabilityDNA

Substanzen

DNA

Autor:innen und Institutionen

  • Università Vita-Salute San Raffaele, Milan, Italy.
  • Division of Experimental Oncology and Center for Omics Sciences, Functional Genomics of Cancer Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Giovanni Tonon

Zitieren

APA

Tonon, G. (2024). Myeloma and DNA damage. Blood. https://doi.org/10.1182/blood.2023021384

Vancouver

Tonon G. Myeloma and DNA damage. Blood. 2024. doi:10.1182/blood.2023021384

BibTeX
@article{Tonon2024,
  author = {Tonon, Giovanni},
  title = {Myeloma and DNA damage},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023021384}
}
Kostenlos starten →